Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, presented results from the CRB-401 trial (NCT02658929) at the 23rd Congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden. This trial used the CAR T-cell therapy bb2121 to treat relapsed/refractory multiple myeloma (MM), and yielded deep responses in patients. The most intriguing finding of this study was that measurable residual disease (MRD) negativity was often achieved before traditional response criteria established by the International Myeloma Working Group (IMWG). This quick MRD response implies that the uses of MRD could be expanded in the future. For example, MRD status could be measured early in treatment to predict depth of response.